| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| irbesartan | type-1 angiotensin ii receptor | small molecule | NA | drugbank , DGIDB | Hypertensive disease[MeSHID:D006973] Serum[MeSHID:D044967] Diabetic Nephropathy[MeSHID:D003928] Diabetes Mellitus Non-Insulin-Dependent[MeSHID:D003924] Proteinuria[MeSHID:D011507] hypertensive nephropathy[MeSHID:C563161] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
2.13 | approved,investigational | antagonist |
| irbesartan | angiotensin ii receptor type-1 | NA | Successful target | TTD , DGIDB | Hypertensive disease[MeSHID:D006973] Serum[MeSHID:D044967] Diabetic Nephropathy[MeSHID:D003928] Diabetes Mellitus Non-Insulin-Dependent[MeSHID:D003924] Proteinuria[MeSHID:D011507] hypertensive nephropathy[MeSHID:C563161] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
2.13 | approved | antagonist |
| irbesartan | type-1 angiotensin ii receptor | small molecule | NA | drugbank , DGIDB | Hypertensive disease[MeSHID:D006973] Serum[MeSHID:D044967] Diabetic Nephropathy[MeSHID:D003928] Diabetes Mellitus Non-Insulin-Dependent[MeSHID:D003924] Proteinuria[MeSHID:D011507] hypertensive nephropathy[MeSHID:C563161] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Coronavirus Infections[MeSHID:D018352] Disease[MeSHID:D004194] |
2.13 | approved,investigational | antagonist |
| irbesartan | angiotensin ii receptor type-1 | NA | Successful target | TTD , DGIDB | Hypertensive disease[MeSHID:D006973] Serum[MeSHID:D044967] Diabetic Nephropathy[MeSHID:D003928] Diabetes Mellitus Non-Insulin-Dependent[MeSHID:D003924] Proteinuria[MeSHID:D011507] hypertensive nephropathy[MeSHID:C563161] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Coronavirus Infections[MeSHID:D018352] Disease[MeSHID:D004194] |
2.13 | approved | antagonist |
| irbesartan | angiotensin ii receptor type-1 | NA | Successful target | TTD , DGIDB | Hypertensive disease[MeSHID:D006973] Serum[MeSHID:D044967] Diabetic Nephropathy[MeSHID:D003928] Diabetes Mellitus Non-Insulin-Dependent[MeSHID:D003924] Proteinuria[MeSHID:D011507] hypertensive nephropathy[MeSHID:C563161] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
2.13 | approved | unknown |
| irbesartan | angiotensin ii receptor type-1 | NA | Successful target | TTD , DGIDB | Hypertensive disease[MeSHID:D006973] Serum[MeSHID:D044967] Diabetic Nephropathy[MeSHID:D003928] Diabetes Mellitus Non-Insulin-Dependent[MeSHID:D003924] Proteinuria[MeSHID:D011507] hypertensive nephropathy[MeSHID:C563161] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Coronavirus Infections[MeSHID:D018352] Disease[MeSHID:D004194] |
2.13 | approved | unknown |
| irbesartan | transcription factor ap-1 | small molecule | NA | drugbank | Hypertensive disease[MeSHID:D006973] Serum[MeSHID:D044967] Diabetic Nephropathy[MeSHID:D003928] Diabetes Mellitus Non-Insulin-Dependent[MeSHID:D003924] Proteinuria[MeSHID:D011507] hypertensive nephropathy[MeSHID:C563161] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,investigational | unknown |
| irbesartan | transcription factor ap-1 | small molecule | NA | drugbank | Hypertensive disease[MeSHID:D006973] Serum[MeSHID:D044967] Diabetic Nephropathy[MeSHID:D003928] Diabetes Mellitus Non-Insulin-Dependent[MeSHID:D003924] Proteinuria[MeSHID:D011507] hypertensive nephropathy[MeSHID:C563161] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Coronavirus Infections[MeSHID:D018352] Disease[MeSHID:D004194] |
NA | approved,investigational | unknown |
| click here to return to the previous page | ||||||||